Moderna Inc said on Wednesday it had dosed the first participant in a mid-stage study testing a booster shot of its vaccine specifically tailored to the fast-spreading Omicron COVID-19 variant.
The company also reported data showing that neutralizing antibodies against the Omicron variant declined six months after a third booster dose of its original vaccine but remained detectable.
Moderna’s Phase 2 trial will test the Omicron-specific booster in adults aged 18 years and older.
It will study the booster in individuals who received only the two-dose primary series of Moderna’s original vaccine, mRNA-1273, and also in those who received the primary series and a booster dose of the same vaccine, the company said.
Pfizer and partner BioNTech earlier this month also started a clinical trial of their vaccine specifically designed to target the Omicron variant.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
